HomeCompareYNDX vs PFE

YNDX vs PFE: Dividend Comparison 2026

YNDX yields 10.56% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $9.4K in total portfolio value· pulled ahead in Year 10
10 years
YNDX
YNDX
● Live price
10.56%
Share price
$18.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$2,047.72
Full YNDX calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — YNDX vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYNDXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YNDX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YNDX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YNDX
Annual income on $10K today (after 15% tax)
$897.57/yr
After 10yr DRIP, annual income (after tax)
$1,740.56/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $20,579.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YNDX + PFE for your $10,000?

YNDX: 50%PFE: 50%
100% PFE50/50100% YNDX
Portfolio after 10yr
$44.9K
Annual income
$14,153.22/yr
Blended yield
31.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YNDX right now

YNDX
Analyst Ratings
20
Buy
3
Hold
2
Sell
Consensus: Buy
Price Target
$79.00
+317.1% upside vs current
Range: $79.00 — $79.00
Altman Z
9188.3
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YNDX buys
4
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$YNDX▼ Sell$1,001 - $15,0002023-06-15
Ro Khanna🏢 House$YNDX▲ Buy$1,001 - $15,0002022-02-14
Ro Khanna🏢 House$YNDX▲ Buy$1,001 - $15,0002022-01-21
Peter Meijer🏢 House$YNDX▼ Sell$1,001 - $15,0002021-02-17
Greg Gianforte🏢 House$YNDX▼ Sell$100,001 - $250,0002020-10-08
Josh Gottheimer🏢 House$YNDX▼ Sell$1,001 - $15,0002020-10-06
Greg Gianforte🏢 House$YNDX▲ Buy$15,001 - $50,0002020-01-13
Greg Gianforte🏢 House$YNDX▼ Sell$15,001 - $50,0002020-01-03
Donna Shalala🏢 House$YNDX▼ Sell$1,001 - $15,0002019-06-24
Greg Gianforte🏢 House$YNDX▲ Buy$15,001 - $50,0002019-04-24
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYNDXPFE
Forward yield10.56%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$40.2K$49.6K
Annual income after 10y$2,047.72$26,258.71
Total dividends collected$15.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$79.00$27.50

Year-by-year: YNDX vs PFE ($10,000, DRIP)

YearYNDX PortfolioYNDX Income/yrPFE PortfolioPFE Income/yrGap
1$11,756$1,055.97$9,153$693.39+$2.6KYNDX
2$13,739$1,160.18$8,593$849.25+$5.1KYNDX
3$15,968$1,267.18$8,336$1,066.78+$7.6KYNDX
4$18,462$1,376.41$8,437$1,384.80+$10.0KYNDX
5$21,242$1,487.30$9,013$1,875.40+$12.2KYNDX
6$24,328$1,599.27$10,306$2,680.72+$14.0KYNDX
7$27,743$1,711.80$12,820$4,101.38+$14.9KYNDX
8$31,509$1,824.37$17,673$6,826.70+$13.8KYNDX
9$35,651$1,936.49$27,543$12,591.86+$8.1KYNDX
10← crossover$40,195$2,047.72$49,560$26,258.71$9.4KPFE

YNDX vs PFE: Complete Analysis 2026

YNDXStock

Yandex N.V., a technology company, builds intelligent products and services powered by machine learning and other technologies to help consumers and businesses navigate the online and offline world. The company operates through Search and Portal, Taxi, Yandex.Market, Media Services, Classifieds, and Other Business Units and Initiatives segments. It provides locally relevant search and information services. The company also develops on-demand transportation, delivery, and navigation services and products, as well as operates in the e-commerce, online entertainment, and cloud computing markets to address the needs of customers in Russia and various international markets. In addition, it operates Yandex.Plus, a subscription loyalty program; offers fintech instruments, such as payment and financial services; and advertising services. Further, the company operates classifieds platforms for the sale of used and new cars, motorcycles, commercial vehicles, and spare parts; and sale and rental of apartments, houses, and commercial property for private individuals, developers, and realtors, as well as a long-term apartment rental platform to manage pre-contract rental processes and subsequent administration of the payments. Additionally, it operates Yandex Zen, a social infotainment platform that brings together content creators and users; and Yandex Cloud, a cloud platform that provides infrastructure, storage, machine learning, and development tools to build and enhance cutting-edge digital services and applications for B2B customers and individual developers. The company was founded in 1989 and is based in Schiphol, the Netherlands.

Full YNDX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this YNDX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YNDX vs SCHDYNDX vs JEPIYNDX vs OYNDX vs KOYNDX vs MAINYNDX vs JNJYNDX vs MRKYNDX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.